Entera Bio (ENTX) Price & Analysis

Compare

425 Followers

ENTX Stock Chart & Stats

$1.46

-$0.11(-4.20%)

At close: Jan 08 4:00 PM EST

$1.46

-$0.11(-4.20%)

Day’s Range― - ―

52-Week Range$1.45 - $3.22

Previous CloseN/A

Volume29.71K

Average Volume (3M)123.78K

Market Cap

$74.75M

Enterprise Value$70.32M

Total Cash (Recent Filing)$8.57M

Total Debt (Recent Filing)$211.00K

Price to Earnings (P/E)―

Beta0.61

Next Earnings

Mar 27, 2026

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding45,857,243

10 Day Avg. Volume240,874

30 Day Avg. Volume123,776

Financial Highlights & Ratios

PEG Ratio0.43

Price to Book (P/B)9.88

Price to Sales (P/S)440.99

P/FCF Ratio-11.70

Enterprise Value/Market Cap0.94

Enterprise Value/Revenue567.09

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-9.32

Forecast

1Y Price Target

$10.00

Price Target Upside584.93% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsEntera Bio achieved alignment with the FDA that a single Phase 3 study with total hip BMD as primary endpoint would support a New Drug Application for a drug to treat post-menopausal osteoporosis.

Product DevelopmentEntera Bio recently announced the presentation of a poster entitled 'A First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome' at the 47th European Society for Clinical Nutrition & Metabolism (ESPEN) Congress, highlighting pharmacokinetic (PK) data relating to its oral GLP-2 analog program.

Regulatory ApprovalFDA ratifies surrogate endpoint use in osteoporosis registrational trials, mitigating significant risks for Entera Bio.

Bears Say

Entera Bio News

Entera Bio ‘congratulates’ FNIH-ASBMR-SABRE team on FDA endpoint qualification

Entera Bio (ENTX) congratulates the FNIH-ASBMR-SABRE team following the Food and Drug Administration broad qualification of total hip...

24d ago

ENTX

Entera Bio announces new data on long-acting PTH tablet

Entera Bio (ENTX) announced new validating in vivo pharmacokinetic and pharmacodynamic data that supports further development of a...

25d ago

ENTX

Entera Bio Reports Q3 2025 Financial Results

Entera Bio ( ($ENTX) ) has released its Q3 earnings. Here is a breakdown of the information Entera...

2M ago

ENTX

Entera Bio Reports Q3 2025 Results and FDA Agreement

An update from Entera Bio ( ($ENTX) ) is now available. Entera Bio announced its third quarter 2025...

2M ago

ENTX

Entera Bio presents clinical data from EB613 Phase 2 trial

Entera Bio (ENTX) reported new clinical data from a post-hoc analysis of its Phase 2 trial of EB613,...

3M ago

ENTX

Entera Bio’s Promising Oral Therapies Drive Buy Rating: Analyst Highlights Developments in GLP-2 and EB613 Programs

Entera Bio, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

4M ago

ENTX

Entera Bio announces presentation of PK data for GLP-2 tablet treatment

Entera Bio (ENTX) announced the presentation of a poster titled “A First-in-Class Oral GLP-2 Analog for Treatment of...

4M ago

ENTX

Entera Bio presents data on EB613 in post-menopausal women with osteoporosis

Entera Bio (ENTX) announced data selected for presentation at the American Society for Bone and Mineral Research 2025...

4M ago

ENTX

Entera Bio to present data across three oral peptide programs

Entera Bio (ENTX) announced that the Company will present data across three key programs during September 2025. American...

5M ago

ENTX

Entera Bio’s Promising Phase 3 Study and Market Potential Drive Buy Rating

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Entera Bio, with a price target of...

5M ago

ENTX

Entera Bio Reports Q2 2025 Financial Results and Strategic Progress

Entera Bio ( ($ENTX) ) has released its Q2 earnings. Here is a breakdown of the information Entera...

5M ago

ENTX

Entera Bio Reports Q2 2025 Financial Results

Entera Bio ( ($ENTX) ) has issued an announcement. Entera Bio announced its second quarter 2025 financial results...

5M ago

ENTX

Entera Bio Advances EB613 with FDA Approval

The latest update is out from Entera Bio ( ($ENTX) ). On July 28, 2025, Entera Bio announced...

6M ago

ENTX

Entera Bio receives FDA agreement on BMD as primary endpoint for EB613 study

Entera Bio (ENTX) announced that in a written response to a Type A meeting request, the U.S. Food...

6M ago

ENTX

ENTX FAQ

What was Entera Bio Ltd’s price range in the past 12 months?

Entera Bio Ltd lowest stock price was $1.45 and its highest was $3.22 in the past 12 months.

What is Entera Bio Ltd’s market cap?

Entera Bio Ltd’s market cap is $74.75M.

When is Entera Bio Ltd’s upcoming earnings report date?

Entera Bio Ltd’s upcoming earnings report date is Mar 27, 2026 which is in 70 days.

How were Entera Bio Ltd’s earnings last quarter?

Entera Bio Ltd released its earnings results on Nov 14, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.02.

Is Entera Bio Ltd overvalued?

According to Wall Street analysts Entera Bio Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Entera Bio Ltd pay dividends?

Entera Bio Ltd does not currently pay dividends.

What is Entera Bio Ltd’s EPS estimate?

Entera Bio Ltd’s EPS estimate is -0.09.

How many shares outstanding does Entera Bio Ltd have?

Entera Bio Ltd has 45,857,243 shares outstanding.

What happened to Entera Bio Ltd’s price movement after its last earnings report?

Entera Bio Ltd reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went down -1.107%.

Which hedge fund is a major shareholder of Entera Bio Ltd?

Currently, no hedge funds are holding shares in ENTX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Entera Bio Stock Smart Score

Underperform

Fundamentals

Return on Equity

-99.43%

Trailing 12-Months

Asset Growth

95.98%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Entera Bio Ltd

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Entera Bio (ENTX) Earnings & Revenues

Historic Earnings Reports

ENTX Stock 12 Month Forecast

Average Price Target

$10.00

▲(584.93% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Aug<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.94,2.56,3.1799999999999997,3.8,4.42,5.04,5.66,6.279999999999999,6.9,7.52,8.14,8.76,9.379999999999999,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.94,2.56,3.1799999999999997,3.8,4.42,5.04,5.66,6.279999999999999,6.9,7.52,8.14,8.76,9.379999999999999,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.94,2.56,3.1799999999999997,3.8,4.42,5.04,5.66,6.279999999999999,6.9,7.52,8.14,8.76,9.379999999999999,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.25,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.83,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.29,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >